PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT06920498
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT06910839
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Vepdegestrant (Reference)Drug: Vepdegestrant (Test)
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT06911788
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
🇳🇱ICON - screening centre, Utrecht, Netherlands
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Not yet recruiting
- Conditions
- Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT06899204
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Not yet recruiting
- Conditions
- Migraine
- Interventions
- Drug: Rimegepant for acute migraine treatment
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT06898047
A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT06897683
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
Phase 3
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINEBiological: HZ/su VACCINE
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 526
- Registration Number
- NCT06890416
- Locations
- 🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸AMR Clinical, Mobile, Alabama, United States
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Phase 3
Recruiting
- Conditions
- Alopecia Areata
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT06873945
- Locations
- 🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸Southern California Clinical Research, Santa Ana, California, United States
🇺🇸Brett King MD, LLC, Fairfield, Connecticut, United States
A Study to Learn More About Tukysa Once it is Out in the Korean Market
Not yet recruiting
- Conditions
- HER2-positive Locally Advanced UnresectableMetastatic Breast Cancer
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT06873191
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.
Phase 1
Recruiting
- Conditions
- Peripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin LymphomaHead and Neck Squamous Cell CarcinomaMelanomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT06870487
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [barcelona], Spain
🇪🇸Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain